Wednesday, July 8, 2026

pharma · Idiopathic Pulmonary Fibrosis · Idiopathic pulmonary fibrosis (IPF) · PLRX

PLIANT THERAPEUTICS

PLIANT THERAPEUTICS clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

South San Francisco, USA HQ
2015 Founded
122 Employees
Public company Type
PLRX · NYSE Ticker
Company details
Status
Public
HQ
South San Francisco, USA
Founded
2015
Employees
122
Programs
6
Drugs
3
Patents
13
Intelligence · Clinical Programs

PLIANT THERAPEUTICS projects

6 ClinicalTrials.gov programs sponsored by PLIANT THERAPEUTICS.

PLIANT THERAPEUTICS has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Bexotegrast, Placebo matching PLN-74809

    PLIANT THERAPEUTICS, INC.

    Idiopathic pulmonary fibrosis (IPF)

    phase 3 small molecule active

    1 trial
  2. PLN-74809

    PLIANT THERAPEUTICS, INC.

    Acute Respiratory Distress Syndrome

    phase 2 small molecule terminated

    1 trial
  3. PLN-74809

    PLIANT THERAPEUTICS, INC.

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    4 trials
  4. PLN-74809

    PLIANT THERAPEUTICS, INC.

    Primary Sclerosing Cholangitis

    phase 2 small molecule completed

    1 trial
  5. PLN-101095

    PLIANT THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial
  6. [18F]FP-R01-MG-F2

    PLIANT THERAPEUTICS, INC.

    Idiopathic Pulmonary Fibrosis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does PLIANT THERAPEUTICS have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.